

Bill Introduced to Strengthen Protections for Child Antipsychotic Prescriptions

Healthcare Law Update

Bill Introduced to Strengthen Protections for Child Antipsychotic Prescriptions

John D. Fanburg
Managing Member & Chair, Healthcare

Edward Hilzenrath
Member, Healthcare

Rebecca T. Falk
Associate, Healthcare

BRACH | EICHLER^{LLC}
Counsellors at Law

2/7/2025

[Assembly Bill 5147](#), introduced in the New Jersey Assembly on December 16, 2024, would require health care providers who are authorized to prescribe psychotropic drugs and participate in NJ FamilyCare to provide information to, and obtain consent from, a parent or guardian before prescribing an antipsychotic drug to a child under the age of 18. Prescribers would be required to provide to the parent or guardian the drug's Medication Guide, information regarding any evidence-based alternatives to the use of the drug and information on how to use and access the FDA's tools to publicly report adverse events. Prescribers would be required to obtain a signed consent form from the child's parent or guardian, indicating that the parent or guardian understands any potential risks or side effects of the drug, is aware of any evidence-based alternatives to the use of the drug and has been informed of the FDA's tools to report adverse effects.

[Click Here to read the entire February 2024 Healthcare Law Update now!](#)

For more information, contact:

John D. Fanburg, Chair | 973.403.3107 | jfanburg@bracheichler.com

Edward Hilzenrath | 973.403.3114 | ehilzenrath@bracheichler.com

Rebecca T. Falk | 973.364.8393 | rfalk@bracheichler.com

Authors

The following attorneys contributed to this insight.



John D. Fanburg

Managing Member
Healthcare Law, Cannabis Industry
973.403.3107 · 973.618.5507 Fax
jfanburg@bracheichler.com



Edward Hilzenrath

Member
Healthcare Law
973.403.3114 · 973.618.5594 Fax
ehilzenrath@bracheichler.com



Rebecca T. Falk

Associate
Healthcare Law
973-364-8393 · 973-618-5923 Fax
rfalk@bracheichler.com